

# AI-Assisted Tool to Improve the Quality and Assessment of PLGA Formulations

**Jayanti Das<sup>1</sup>, Md Easin Hasan<sup>1</sup>, William Smith<sup>1</sup>, John Garner<sup>2</sup>, Bin Qin<sup>3</sup>, Yan Wang<sup>3</sup>, Kinam Park<sup>2,4</sup>, Geng Tian<sup>1</sup>, Xiaoming Xu<sup>1</sup>**

<sup>1</sup>Division of Product Quality Research, Office of Testing and Research, OPQ, CDER, USA, <sup>2</sup>Akina, Inc., West Lafayette, IN 47906, USA,

<sup>3</sup>Division of Therapeutic Performance I, Office of Research and Standards, OGD, CDER, U.S. FDA, <sup>4</sup>Purdue University, Biomedical Engineering and Pharmaceutics, West Lafayette, IN 47907, USA



# SUMMARY

- ❖ The AI-based method provides high-throughput analysis of PLGA (poly(lactic-co-glycolic acid))-based long-acting injectable (LAI) formulations to establish a correlation between material attributes, processing conditions, and product quality/performance.
- ❖ This AI method may serve as a tool in the future to evaluate the sameness of proposed generic products to reference listed drugs (RLD) by analyzing feature similarity across different formulations.

# METHODS

- ❖ The study has compiled a comprehensive dataset of PLGA formulations from a previous FDA-funded research project [1].
- ❖ The dataset includes different formulation details, corresponding manufacturing data, detailed surface topographical characterization data due to solvent changes, and *in vitro* release testing data [1].




Fig 3: Principal component analysis (PCA) on the left and correlation matrix study on the right to find significant parameters




Fig 1: Microparticles of formulations in the dry state and after exposure to a semi-solvent liquid at 0°C for 1 min and details of previous work in the QR code [1]




Fig. 2: Functional flow of the work

## REFERENCE

1. Surface analysis of sequential semi-solvent vapor impact (SAVI) for studying microstructural arrangements of poly (lactide-co-glycolide) microparticles; John Garner, Sarah Skidmore, Justin Hadar, Haesum Park, Kinam Park, Bin Qin, Yan Wang; Journal of Controlled Release, 2022, 350, 600-612

# ACKNOWLEDGEMENT

The dataset for this study was from a previously FDA funded research project (BAA#75F40119C10096).




Fig 4: Prediction of IVRT profiles and compared with experimental release profiles

# DISCLAIMER

The views expressed in this work reflect the views of authors and do not reflect the official policies of the U.S. Food and Drug Administration or the U.S. Department of Health and Human Services.